FDA's Center for Drug Evaluation and Research intends to argue at a June hearing that the accelerated approval system will operate as a lower standard if bevacizumab's breast cancer indication is maintained while Genentech conducts another confirmatory trial.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
